Genertec Universal Medical : ANNOUNCEMENT IN RELATION TO THE PROPOSED ISSUANCE OF DOMESTIC MEDIUM-TERM NOTES IN THE PRC BY CHINA UNIVERSAL LEASING CO., LTD., A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GENERTEC UNIVERSAL MEDICAL GROUP COMPANY

LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code：2666)

ANNOUNCEMENT IN RELATION TO THE PROPOSED ISSUANCE OF

DOMESTIC MEDIUM-TERM NOTES IN THE PRC

BY CHINA UNIVERSAL LEASING CO., LTD., A WHOLLY-OWNED

SUBSIDIARY OF THE COMPANY

This announcement is made by Genertec Universal Medical Group Company Limited (the "Company") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

China Universal Leasing Co., Ltd. ( 中 國 環 球 租 賃 有 限 公 司 ) (the "Issuer"), a wholly-owned subsidiary of the Company, had registered the issuance of the domestic medium-term notes with the National Association of Financial Market Institutional Investors (中國銀行間市場交易商協會) of an aggregate principal amount of up to RMB1.6 billion in the People's Republic of China (the "PRC"). The issuer has decided to launch the issuance of the first tranche of the domestic medium- term notes in the PRC with an aggregate principal amount of up to RMB1 billion (the "T1 Notes"). The T1 Notes have a term of two years and a fixed interest rate which will be determined at the end of the subscription period through book-building processes. The net proceeds from issuance of the T1 Notes are intended to be used for repaying maturing debts of the Issuer.

1

The T1 Notes will be issued to domestic institutional investors in the PRC (other than those who are restricted from participating in such offering in accordance with the laws and regulations of the PRC). CITIC Securities Company Limited (中信證券股份有限公司) and Bank of China Limited (中國銀行股份有限公司) are the joint lead underwriters for the issuance of the T1 Notes.

Other principal terms of the T1 Notes to be issued are as follows:

In accordance with the relevant laws and regulations in the PRC, relevant documents in relation to the Issuer and the T1 Notes will be published on the websites of Shanghai Clearing House

(http://www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) , respectively. Shareholders of the Company and potential investors are reminded that such documents were prepared in accordance with the requirements in the PRC and are limited solely to the Issuer, and the information contained therein does not provide a full picture of the operation status of the Company and its subsidiaries.

Further announcement(s) will be made by the Company in relation to the updated progress of issuance of the T1 Notes as and when appropriate.

By order of the Board

Genertec Universal Medical Group Company

Limited

通用環球醫療集團有限公司

Peng Jiahong

Executive Director

Beijing, PRC, 31 March 2021

2

As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Vice-chairwoman) and Mr. Yu Gang; the non-executive directors of the Company are Mr. Zhang Yichen (Chairman), Ms. Liu Kun and Mr. Liu Zhiyong; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Han Demin and Mr. Liao Xinbo.

2